会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明授权
    • Plasmids comprising a genetically altered feline immunodeficiency virus genome
    • 质粒包含遗传改变的猫免疫缺陷病毒基因组
    • US06300118B1
    • 2001-10-09
    • US08479703
    • 1995-06-07
    • Lloyd ChavezTerri WasmoenChengjin Huang
    • Lloyd ChavezTerri WasmoenChengjin Huang
    • C12N1563
    • C12N15/8509A01K2217/05A01K2227/10A01K2267/01A01K2267/0337A61K39/00C07K14/005C12N2740/15022
    • The present invention pertains to the prevention or lessening of disease in cats caused by Feline Immunodeficiency Virus (FIV). Prevention or lessening of disease is understood to mean the amelioration of any symptoms, including immune system disruptions, that result from FIV infection. The invention provides for a plasmid which encodes the FIV genome where said genome has had a portion of the gag gene, specifically the p10 (nucleocapsid) coding region, or a portion thereof, deleted. This deletion prevents the production of functional or whole p10 protein, which in turn, prevents the packaging of RNA into virions produced from transfection of this plasmid into an appropriate host cell, resulting in virions which do not contain RNA. Such virions will be described as “empty” virions. The invention also encompasses host cells transformed with the plasmid which produce the empty virions, and the empty virions themselves. In another embodiment, the invention encompasses vaccines that comprise one or more empty virions described above, with a pharmaceutically acceptable carrier or diluent and a pharmaceutically acceptable adjuvant. In yet another aspect, the invention provides methods for preventing or lessening disease caused by FIV, which is carried out by administering to a feline in need of such treatment the vaccines described above.
    • 本发明涉及由猫免疫缺陷病毒(FIV)引起的猫的疾病的预防或减轻。 理解疾病的预防或减轻意味着由FIV感染引起的任何症状(包括免疫系统中断)的改善。 本发明提供编码FIV基因组的质粒,其中所述基因组具有一部分gag基因,特别是p10(核衣壳)编码区或其部分缺失。 该缺失可防止功能性或整个p10蛋白的产生,这反过来又防止了将RNA包装在由该质粒转染到合适的宿主细胞中而产生的病毒颗粒中,导致不含有RNA的病毒粒子。 这样的病毒粒子将被描述为“空”病毒粒子。 本发明还包括用产生空病毒粒子的质粒转化的宿主细胞,以及空的病毒粒子本身。 在另一个实施方案中,本发明包括包含一种或多种如上所述的空病毒体与药学上可接受的载体或稀释剂和药学上可接受的佐剂的疫苗。 另一方面,本发明提供了预防或减轻由FIV引起的疾病的方法,其通过向需要这种治疗的猫科动物施用上述疫苗来进行。
    • 6. 发明授权
    • Cloning genes from Streptomyces cyaneogriseus subsp. Noncyanogenus for biosynthesis of antibiotics and methods of use
    • 从链霉菌(Cytotomyces cyaneogriseus)亚种克隆基因 非生物素用于生物合成抗生素及使用方法
    • US07396660B2
    • 2008-07-08
    • US10844716
    • 2004-05-13
    • Chengjin HuangDeborah T. ChaleffMark E. RuppenJerome Stephens
    • Chengjin HuangDeborah T. ChaleffMark E. RuppenJerome Stephens
    • C12P19/44C12N15/52C12N15/70C12N15/76
    • C12N9/0004C12N9/1007C12N9/16C12N15/52C12P17/181
    • The present invention relates to the complete biosynthetic pathway for the formation of the LL-F28249 compounds and, most importantly, the major component LL-F28249α. The purified and isolated nucleic acid molecule encoding the proteins of the biosynthetic pathway, which is isolated from a wild-type or mutant Streptomyces, is fully described in FIG. 6 to FIG. 6-39 and SEQ ID NO:1. The DNA gene cluster and its expression in a suitable host enable the efficient production of the highly active natural metabolites and semisynthetic derivatives. The invention further concerns plasmids, vectors and host cells that contain and express the novel nucleic acid molecule. Of particular interest, the entire biosynthetic pathway fits compactly in three plasmids, Cos11, Cos36 and Cos40. The invention also concerns the purified and isolated biosynthesis proteins that are encoded by the whole DNA gene cluster. Additionally, the invention involves a new efficient, biochemical method of preparing moxidectin.
    • 本发明涉及用于形成LL-F28249化合物的完整生物合成途径,最重要的是涉及主要成分LL-F28249α。 编码从野生型或突变链霉菌分离的生物合成途径的蛋白质的纯化和分离的核酸分子在图1中完全描述。 参照图6〜 6-39和SEQ ID NO:1。 DNA基因簇及其在合适的宿主中的表达使得能够高效生产高活性的天然代谢物和半合成衍生物。 本发明还涉及含有和表达新型核酸分子的质粒,载体和宿主细胞。 特别令人感兴趣的是,整个生物合成途径紧密地适应于三种质粒Cos11,Cos36和Cos40。 本发明还涉及由整个DNA基因簇编码的纯化和分离的生物合成蛋白。 此外,本发明涉及制备莫昔克丁的新的有效的生物化学方法。